NCT02541604 · OUTCOME

DOR as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)

Analysis population: Included safety-evaluable population, defined as patients who received any amount of study drug.

Groups in this outcome

Cohort 2

Participants with hodgkin lymphoma.

Cohort 4

Participants with non-hodgkin's lymphoma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort 2	2
Cohort 4	1

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Cohort 2	NA	Not reported	4.1	NA	Kaplan-Meier median estimate not reached.
Cohort 4	NA	Not reported	NA	NA	Kaplan-Meier median estimate not reached.

Complete source fields

classes

categories
measurements
comment
Kaplan-Meier median estimate not reached.
group Id
OG000
lower Limit
4.1
upper Limit
NA
value
NA
comment
Kaplan-Meier median estimate not reached.
group Id
OG001
lower Limit
NA
upper Limit
NA
value
NA

denoms

counts
group Id
OG000
value
2
group Id
OG001
value
1
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Participants with hodgkin lymphoma.
id
OG000
title
Cohort 2
description
Participants with non-hodgkin's lymphoma
id
OG001
title
Cohort 4

param Type

MEDIAN

population Description

Included safety-evaluable population, defined as patients who received any amount of study drug.

reporting Status

POSTED

time Frame

Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)

title

DOR as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice